- Under the terms of the agreement, Lotus will be responsible for the commercialization of Ryaltris™ (subject to receipt of regulatory approvals), while Glenmark will be responsible for the manufacture and supply of Ryaltris™ across these markets.
- RyaltrisTM, developed by Glenmark, is a novel, fixed-dose combination nasal spray of an anti-histamine (olopatadine hydrochloride) and a steroid (mometasone furoate), indicated for treatment of symptoms associated with allergic rhinitis (AR) in patients over 12 years of age.
Lotus Pharmaceutical (1795:TT), a multinational pharmaceutical company, today announced that its wholly owned subsidiary, Lotus International Pte. Ltd., has signed a licensing agreement with Glenmark Specialty S.A., a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd. (“Glenmark”) for commercializing its innovative nasal spray Ryaltris™ in Singapore, Hong Kong and Vietnam.
Under the terms of the agreement, Lotus will be responsible for commercialization of Ryaltris™ (subject to receipt of regulatory approvals), across these markets, while Glenmark will be responsible for manufacture and supply of Ryaltris™.
Ryaltris™ is a metered, fixed-dose, aqueous suspension, prescription drug product nasal spray approved for the treatment of symptoms associated with allergic rhinitis in adults and pediatric patients 12 years of age and older. As allergic rhinitis is a heterogeneous disorder that despite its high prevalence is often undiagnosed, it contributes to missed or unproductive time at work, sleep problems and decreased involvement in outdoor activities. Allergic rhinitis can be seasonal (occurring during specific seasons) or perennial (occurring year-round).
Petar Vazharov, Chief Executive Officer of Lotus, said, “As being strongly committed to making a difference for all patients, we are honored to partner with Glenmark to ensure this novel spray drug accessible to patients in South East Asia. This is also the first Brand product to be included in our respiratory portfolio with strong clinical data and IP protection. The partnership not only strengthens the competitiveness of our overall product portfolio but also accelerates our expansion in key SEA countries.”
“We are excited to partner with Lotus for Ryaltris™ as it is a strong and reputed player in the region and is aligned with Glenmark’s objective to provide quality novel products to fulfill unmet needs of patients with allergic rhinitis. This partnership will help provide patients, a highly effective and proven treatment for allergic rhinitis, in these key South-East Asian markets,” said Robert Crockart, Chief Commercial Officer, Glenmark Pharmaceuticals Ltd.
Prevalence of allergic rhinitis is 4.2% in Hong Kong, 4.9% in Singapore and 12.3% in Vietnamii. Being a topical therapy Ryaltris™ offers many advantages over oral therapies, such as delivering greater concentrations of drug to the receptor sites at the source of the allergic inflammation and reduced risk of systemic side effects.